Visiomed Group SA
PAR:ALVMG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.1646
0.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Visiomed Group SA
Visiomed Group SA
Cost of Revenue
Visiomed Group SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Visiomed Group SA
PAR:ALVMG
|
Cost of Revenue
-€789k
|
CAGR 3-Years
64%
|
CAGR 5-Years
30%
|
CAGR 10-Years
17%
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Cost of Revenue
-€36m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Biomerieux SA
PAR:BIM
|
Cost of Revenue
-€1.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Carmat SA
PAR:ALCAR
|
Cost of Revenue
-€35.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-8%
|
|
|
Biosynex SA
PAR:ALBIO
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Cost of Revenue
-€21.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Visiomed Group SA
Glance View
Visiomed Group SA engages in the development and distribution of healthcare products and services. The company is headquartered in Puteaux, Ile-De-France. The company went IPO on 2011-07-05. The firm is primarily engaged in the design, manufacture and marketing of medical electronics. The company develops and markets health products in the fields of medical and well-being self-diagnosis to provide non-drug prevention and treatment solutions. The firm's product portfolio comprises MyThermo, an infrared contact-less medical thermometer; MyTension, an automatic blood pressure and pulse monitors; MyOxy, a finger pulse oximeter; MyECG, a pocket electrodiogram; MyGluco, a blood sugar meter; My Coach, a health and fitness coach, and Epiderm, a telemedicine dermatology mobile application, among others. The firm serves pharmacies, health professionals, hospitals, clinics and retirement homes. The company also offers connected solutions and COVID devices such as deconfinement kits, masks, filter cushion, serological tests etc. The Company’s subsidiaries include ThermoFlash and BewellConnect.
See Also
What is Visiomed Group SA's Cost of Revenue?
Cost of Revenue
-789k
EUR
Based on the financial report for Dec 31, 2023, Visiomed Group SA's Cost of Revenue amounts to -789k EUR.
What is Visiomed Group SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
17%
Over the last year, the Cost of Revenue growth was 77%. The average annual Cost of Revenue growth rates for Visiomed Group SA have been 64% over the past three years , 30% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
